Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism.

Clinical pharmacology and therapeutics - 1 Apr 2012

Liu Y, Jeong H, Takahashi H, Drozda K, Patel S R, Shapiro N L, Nutescu E A, Cavallari L H

Abstract excerpt

The cytochrome P450 (CYP) 2C9 R150H (*8) allele occurs commonly in African Americans and is associated with lower warfarin dose requirements. We conducted a pharmacokinetic study to examine whether the CYP2C9*8 allele impacts warfarin clearance in African-American patients. We also conducted an i...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aryl Hydrocarbon Hydroxylases
Share to Black or African American

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Hep G2 Cells

Share to Metabolic Clearance Rate

Share to Polymorphism, Genetic

Share to Warfarin

Source

Open in PubMed Open full text

Identifiers

PMID: 22378156
DOI: 10.1038/clpt.2011.269
PMCID: PMC3879795

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22378156-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism.PMID 22378156Read ↗

CYP2C9 promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in CYP2C9*8-mediated effects.Semantic proximity Read ↗

Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans.Semantic proximity Read ↗

Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans.Semantic proximity Read ↗

The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase.Semantic proximity Read ↗

Insights into the Genetic Variations of Human Cytochrome P450 2C9: Structural Analysis, Characterization and Comparison.Semantic proximity Read ↗

Identification and characterization of a novel CYP2C9 allelic variant in a warfarin-sensitive patient.Semantic proximity Read ↗

Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing.Semantic proximity Read ↗

Characterization of a novel CYP2C9 mutation (1009C>A) detected in a warfarin-sensitive patient.Semantic proximity Read ↗

In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose.Semantic proximity Read ↗

Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms.Semantic proximity Read ↗

5'-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients.Semantic proximity Read ↗

CYP2C9 Genotype-Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.